NFASC and neuropathy: Recently a single 52-year-old patient affected by a severe neuropathy with antibodies to neurofascin and concomitant late onset nemaline myopathy as well as smoldering multiple myeloma, was treated with daratumumab, the humanized anti-CD38 monoclonal antibody targeting long-lived plasma cells, after failure of several therapies, including steroids, plasma-exchange and rituximab [46].